Imayavaramban Lakshmanan, PhD
Research
Dr. Lakshmanan's research team is evaluating the impact of tumor cell sialylation on immune evasion, tumor angiogenesis and brain metastasis. Specifically, they are investigating the role of
sialyltransferase ST6GalNAc-I in NECTIN2 sialylation, which adds α2,6-linked sialic acid, in
lung adenocarcinoma cells and its effect on T cell dysfunction. Mechanistically, sialylated NECTIN2 promotes T cell dysfunction by interacting with TIGIT (T cell immunoglobulin and ITIM
domain), an inhibitory receptor. This laboratory also examines the role of sialylated MUC5AC in tumor angiogenesis and brain metastasis.
Additionally, Dr. Lakshmanan's laboratory has focused on how connexin 31 (Gjb3) regulates sialic acid metabolism through Cytidine Monophosphate N-Acetylneuraminic Acid Synthetase in lung
adenocarcinoma. Their research concentrates on sialic acid metabolism and how tumor cell
sialylation impacts lung adenocarcinoma development and brain metastasis. To accomplish this, they are employing various innovative approaches using 3D in vitro models and genetically
engineered mouse models. They have developed multiple syngeneic cell lines and organoids
from genetically engineered mouse models to test different chemotherapeutic or molecularly
targeted drugs.
University of Nebraska Medical Center
985870 Nebraska Medical Center
Omaha, NE 68198-5870